SCHEMBL3178928

SCHEMBL3178928

Cc1csc2c(=O)n(-c3ccc(F)cc3)c(C3CCC(C(F)(F)F)CC3)nc12

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.36
NPSR1 Q6W5P4 2/20 0.36
PDE4B Q07343 1/20 0.36
PDE7A Q13946 1/20 0.36
TGM2 P21980 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
GRM1 Q13255 2/20 0.33
TSHR P16473 1/20 0.32
HTT P42858 1/20 0.32
DRD1 P21728 3/20 0.31
DRD5 P21918 3/20 0.31
AOC3 Q16853 1/20 0.31
POLB P06746 1/20 0.31
TACR2 P21452 1/20 0.31
TACR3 P29371 1/20 0.31
RXFP1 Q9HBX9 1/20 0.31
SCN9A Q15858 1/20 0.31
HSD17B10 Q99714 1/20 0.31
DPP4 P27487 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3178920 1.00 KDM4E (0.36) KDM4ENPSR1PDE4BPDE7ATGM2
SCHEMBL3175361 0.91 POLB (0.39) PDE4BPDE7ASMN1; SMN2GRM1DRD1
SCHEMBL3175372 0.91 POLB (0.39) PDE4BPDE7ASMN1; SMN2GRM1DRD1
SCHEMBL3169324 0.85 PDE4B (0.33) PDE4BPDE7ASMN1; SMN2
SCHEMBL3169334 0.85 PDE4B (0.33) PDE4BPDE7ASMN1; SMN2
SCHEMBL13660351 0.78 SMN1; SMN2 (0.34) PDE4BPDE7ASMN1; SMN2GRM1POLB
SCHEMBL13532363 0.76 HSD17B10 (0.37) NPSR1TSHRDRD1DRD5SCN9A
SCHEMBL4755656 0.75 MEN1 (0.39) KDM4ESMN1; SMN2AOC3POLBSCN9A
SCHEMBL4755659 0.75 MEN1 (0.39) KDM4ESMN1; SMN2AOC3POLBSCN9A
SCHEMBL3178194 0.74 DRD1 (0.38) SMN1; SMN2DRD1DRD5AOC3SCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100008866-A1 CIS-CYCLOHEXYL SUBSTITUTED PYRIMIDINONE DERIVATIVES NEUROGEN CORPORATION (US) 2010-01-14 US claimed
EP-2094704-A2 CIS-CYCLOHEXYL SUBSTITUTED PYRIMIDINONE DERIVATIVES Neurogen Corporation (US) 2009-09-02 EP claimed
WO-2008066664-A2 CIS-CYCLOHEXYL SUBSTITUTED PYRIMIDINONE DERIVATIVES NEUROGEN CORPORATION (US) 2008-06-05 WO claimed
US-20100008866-A1 CIS-CYCLOHEXYL SUBSTITUTED PYRIMIDINONE DERIVATIVES NEUROGEN CORPORATION (US) 2010-01-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100008866-A1 CIS-CYCLOHEXYL SUBSTITUTED PYRIMIDINONE DERIVATIVES PIGS, GPR174, GPR17 KDM4E 3610/4885NPSR1 88/4885PDE4B 1345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.